| Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update |
Resolution of CRL Manufacturing issues in progress - Type A meeting requested N o clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-14 11:04:00 |
Czytaj oryginał (ang.) |
| Stock Picks From Seeking Alpha's March 2025 New Analysts |
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl. |
seekingalpha.com |
2025-04-04 18:30:59 |
Czytaj oryginał (ang.) |
| MIST Stock Falls 66% Following Complete Response Letter for Cardamyst |
Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues. |
zacks.com |
2025-04-02 20:00:36 |
Czytaj oryginał (ang.) |
| US FDA declines to approve Milestone Pharma's heart rhythm nasal spray |
The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' nasal spray to treat a type of heart condition, the company said on Friday. |
reuters.com |
2025-03-28 09:06:31 |
Czytaj oryginał (ang.) |
| FDA Issues Complete Response Letter for Etripamil for PSVT |
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of PSVT to sinus rhythm in adults. |
globenewswire.com |
2025-03-28 09:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers |
In December 2023, Milestone Pharmaceuticals received an RTF letter from the FDA for insufficient TEAE data in their NDA filing, which precipitated a rapid decline in its share price. With an upcoming PDUFA in the PSVT indication, the company is approaching a binary event that will largely determine its future on the market. Considering Milestone's 2,000 patients worth of drug data across five clinical trials, we believe approval to be imminent for Etripamil and recommend a long position. |
seekingalpha.com |
2025-03-21 17:18:08 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology |
MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29th to 31st, 2025 in Chicago, Illinois. |
globenewswire.com |
2025-03-20 10:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update |
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) |
globenewswire.com |
2025-03-13 09:08:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 94,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of four new hires. |
globenewswire.com |
2025-03-04 10:00:00 |
Czytaj oryginał (ang.) |
| DONNA KARAN CASHMERE MIST INTRODUCES A NEW CHAPTER FOR SPRING 2025, FEATURING IMAAN HAMMAM IN A CAPTIVATING CAMPAIGN |
NEW YORK , Feb. 28, 2025 /PRNewswire/ -- Donna Karan New York is relaunching its iconic Cashmere Mist Eau de Parfum, with a bold new campaign featuring globally renowned supermodel, Imaan Hammam debuting in February 2025. The campaign reintroduces the fragrance's timeless sensuality with a fresh, modern edge that speaks directly to today's multifaceted woman. |
prnewswire.com |
2025-02-28 11:01:00 |
Czytaj oryginał (ang.) |
| Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference |
MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil |
MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) on a new Method of Use patent for etripamil nasal spray (proposed trade name CARDAMYST™), its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT). |
globenewswire.com |
2025-02-19 10:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025 |
MONTREAL and CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced further details on its in-person and virtual Commercial Launch Plan investor event to take place in New York on Tuesday, February 25, 2025 from 10:30 AM to 12:30 PM ET. |
globenewswire.com |
2025-02-11 10:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC |
- PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) |
globenewswire.com |
2025-01-28 10:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 113,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires. |
globenewswire.com |
2025-01-07 10:00:00 |
Czytaj oryginał (ang.) |
| After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright |
Milestone Pharmaceuticals Inc. (MIST) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MIST's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross. |
zacks.com |
2024-11-19 12:56:27 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update |
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 |
globenewswire.com |
2024-11-12 11:03:00 |
Czytaj oryginał (ang.) |
| Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China |
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline results from a multi-center, randomized, double-blind, placebo-controlled trial in China evaluating the efficacy and safety of etripamil nasal spray in paroxysmal supraventricular tachycardia (PSVT). The trial design closely matched the RAPID Phase 3 Study of etripamil in PSVT conducted by Milestone in North America and Europe. |
globenewswire.com |
2024-09-06 11:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors |
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024. |
globenewswire.com |
2024-09-04 12:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update |
– NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik Appointed as Independent Board Directors MONTREAL and CHARLOTTE, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the second quarter ended June 30, 2024 and provided a regulatory and corporate update. |
globenewswire.com |
2024-08-08 20:17:00 |
Czytaj oryginał (ang.) |
| 4 Stocks Under $5 To Buy Now |
Are you looking for stocks to buy with low price tags? |
247wallst.com |
2024-08-08 17:05:04 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024 |
MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will host Part I of its virtual investor educational series on Thursday, June 20, 2024, at 8:00 AM ET. To register for “Learnings from the Field: Expert Perspectives on Managing PSVT in the Community Setting,” click here . |
globenewswire.com |
2024-06-12 12:00:00 |
Czytaj oryginał (ang.) |
| Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference |
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024. |
globenewswire.com |
2024-05-31 12:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™ |
MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the United States Food and Drug Administration (FDA) accepted the Company's New Drug Application (NDA) on May 26, 2024 for CARDAMYST (etripamil) nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT). The FDA Prescription Drug User Fee Act (PDUFA) target date is 10 months from the acceptance date of May 26, 2024. |
globenewswire.com |
2024-05-29 11:00:00 |
Czytaj oryginał (ang.) |
| Brokers Set Expectations for Milestone Pharmaceuticals Inc.’s Q2 2024 Earnings (NASDAQ:MIST) |
Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Investment analysts at HC Wainwright boosted their Q2 2024 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a report released on Thursday, May 16th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.13) for the quarter, up from their prior forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.59) EPS, FY2025 earnings at ($0.70) EPS, FY2026 earnings at ($0.45) EPS, FY2027 earnings at $0.56 EPS and FY2028 earnings at $1.67 EPS. Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Separately, Piper Sandler lowered their price target on Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 5th. Get Our Latest Analysis on MIST Milestone Pharmaceuticals Price Performance NASDAQ:MIST opened at $1.74 on Monday. The stock has a fifty day moving average of $1.67 and a 200 day moving average of $1.96. Milestone Pharmaceuticals has a 52-week low of $1.33 and a 52-week high of $4.39. The company has a debt-to-equity ratio of 1.27, a quick ratio of 10.11 and a current ratio of 22.75. The firm has a market capitalization of $92.67 million, a price-to-earnings ratio of -1.39 and a beta of 1.77. Institutional Inflows and Outflows A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. BML Capital Management LLC lifted its stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) by 37.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 606,145 shares of the company’s stock after buying an additional 163,793 shares during the period. Milestone Pharmaceuticals makes up approximately 0.7% of BML Capital Management LLC’s holdings, making the stock its 21st largest holding. BML Capital Management LLC owned about 1.14% of Milestone Pharmaceuticals worth $1,085,000 as of its most recent SEC filing. Institutional investors and hedge funds own 86.18% of the company’s stock. About Milestone Pharmaceuticals (Get Free Report) Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. |
https://www.defenseworld.net |
2024-05-20 05:38:48 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know |
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-05-16 17:01:33 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update |
– NDA for etripamil in PSVT resubmitted in 1Q 2024 – Cash resources as of March 31, 2024 expected to fund operations into 2026 – Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR is progressing |
globenewswire.com |
2024-05-13 11:15:00 |
Czytaj oryginał (ang.) |
| Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium |
MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL. The posters will be available following the embargo at https://MilestonePharma.com. |
globenewswire.com |
2024-04-17 12:00:00 |
Czytaj oryginał (ang.) |
| Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting |
Data from this large safety-trial also published in The Journal of the American College of Cardiology Data from this large safety-trial also published in The Journal of the American College of Cardiology |
globenewswire.com |
2024-04-08 15:36:00 |
Czytaj oryginał (ang.) |
| Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences |
MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver oral and poster presentations at the American College of Cardiology annual meeting (ACC24), to be held April 6-8th in Atlanta, Georgia, and a poster presentation at the annual meeting of the European Heart Rhythm Association (EHRA), to be held April 7-9th in Berlin, Germany. The presentations will be available following the embargo at https://MilestonePharma.com. |
globenewswire.com |
2024-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update |
- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting expected mid-2024 MONTREAL and CHARLOTTE, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate update. |
globenewswire.com |
2024-03-21 09:14:00 |
Czytaj oryginał (ang.) |
| Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference |
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024, at 10:30am ET. |
globenewswire.com |
2024-02-29 18:01:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants |
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 16,666,667 of its common shares (the “Shares”) at a public offering price of $1.50 per share and (ii) in lieu of common shares, pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such pre-funded warrant (“Pre-Funded Warrants” and, together with the Shares the “Securities”). The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $30.0 million. In addition, Milestone has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 common shares at the public offering price, less underwriting commissions. The Offering is expected to close on or about March 4, 2024, subject to satisfaction of customary closing conditions. |
globenewswire.com |
2024-02-29 09:00:00 |
Czytaj oryginał (ang.) |
| Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants |
MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares (the “Shares,”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares (“Pre-Funded Warrants” and, together with the Shares, the “Securities”). In addition, Milestone expects to grant the underwriters a 30-day option to purchase a number of additional common shares equal to 15% of the Securities offered in the Offering. All Securities to be sold in the Offering will be sold by the Company. The Offering is subject to market and other conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. |
globenewswire.com |
2024-02-28 18:37:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST |
NEW YORK , Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ: MIST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-01-22 21:16:00 |
Czytaj oryginał (ang.) |